Company Overview and News

24
Why is Model N (MODN) Up 4.8% Since Its Last Earnings Report?

2018-06-07 zacks
It has been about a month since the last earnings report for Model N, Inc. (MODN - Free Report) . Shares have added about 4.8% in that time frame.
ENL CRAI MODN ENDP

164
Top Stock Reports for Mastercard, NVIDIA & Danaher

2018-05-14 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), NVIDIA (NVDA) and Danaher (DHR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
STQN ADP MA NVDA BRK.A ADPVV GM.WS.A GM.WS.B GM.WS.C ICE GM OXY GM.WSB DHR MODN

20
Model N (MODN) Earnings & Revenues Beat Estimates in Q2

2018-05-09 zacks
Model N, Inc. (MODN - Free Report) reported second-quarter fiscal 2018 earnings of 2 cents per share against the year-ago quarter’s loss of 25 cents per share. The Zacks Consensus Estimate was pegged at a loss of 4 cents per share.
WDAY AZPN MODN CDNS

0
Model N: No Reasons To Buy

2018-05-09 seekingalpha
Model N also announced that founder Zack Rinat will step down as CEO, to be replaced by outsider Jason Blessing. This will be Rinat's second exit as CEO.
MODN

0
MODN / Model N, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov
modn-10q_20180331.htm UNITED STATES
MODN

33
Model N's (MODN) CEO Zack Rinat on Q2 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Greetings and welcome to the Model N Second Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to your host, Staci Mortenson, Investor Relations for Model N. Staci, please go ahead.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN IDTI WFC.PRY WFC.PRX WFC.PRW WFC.PRV MODN

0
MODN / Model N, Inc. 8-K (Current Report)

2018-05-08 sec.gov
modn-8k_20180504.htm UNITED STATES
MODN

0
MODN / Model N, Inc. 8-K RE TRANSITION (Current Report)

2018-05-08 sec.gov
modn-8k_20180506.htm UNITED STATES
MODN

16
Model N (MODN) to Report Q2 Earnings: What's in the Cards?

2018-05-04 zacks
Model N Inc. (MODN - Free Report) is scheduled to report second-quarter fiscal 2018 earnings on May 8.
LVS PF INTC MODN

0
Orion can return to profit without raising capital, says CFO

2018-04-05 nzherald.co.nz
Orion Health Group, whose shares hit a record low this week after the company cut guidance for the third time, can reach profitability with further cost-cutting and may not need to raise more capital, says chief financial officer Mark Tisdel.
WYN OHE MODN

0
MODN / Model N, Inc. S-8

2018-03-30 sec.gov
modn-s8.htm As filed with the Securities and Exchange Commission on March 30, 2018 Registration No. 333-
MODN

108
Key Reasons to Add Model N (MODN) Stock to Your Portfolio

2018-03-28 zacks
With stellar first-quarter fiscal 2018 results, acquisition synergies, Software-as-a-Service (SaaS) based model and strong fundamentals; Model N, Inc. (MODN - Free Report) appears a promising pick right now. Moreover, it has been a favorite with investors, courtesy of its rising share price.
FB STX NVDA MODN

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 607525102